StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The substantial target increase supports a bullish view, but it remains an analyst opinion rather than a confirmed change in fundamentals.
What happened, with direct paths to the underlying reporting
Leerink raised its Replimune target to $31 from $19. The new target is about 78% above the posted price of $17.42.
Target: $31
Posted price: $17.42
Analyst firm: Leerink Partners
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.